KRW 103600.0
(-2.54%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 94.48 Billion KRW | -37.12% |
2022 | 150.25 Billion KRW | 1365.01% |
2021 | 10.25 Billion KRW | -24.43% |
2020 | 13.57 Billion KRW | 131.67% |
2019 | 5.85 Billion KRW | 0.0% |
2018 | - KRW | 0.0% |
2017 | - KRW | 0.0% |
2016 | - KRW | 0.0% |
2015 | - KRW | 0.0% |
2014 | - KRW | 0.0% |
2013 | - KRW | 0.0% |
2012 | - KRW | 0.0% |
2011 | - KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 25 Billion KRW | 0.0% |
2024 Q1 | 25 Billion KRW | -73.54% |
2023 Q1 | 125.63 Billion KRW | -16.38% |
2023 Q2 | 125.18 Billion KRW | -0.36% |
2023 Q3 | 96.39 Billion KRW | -22.99% |
2023 Q4 | 94.48 Billion KRW | -1.98% |
2023 FY | 94.48 Billion KRW | -37.12% |
2022 Q2 | 53.43 Billion KRW | 4.72% |
2022 FY | 150.25 Billion KRW | 1365.01% |
2022 Q4 | 150.25 Billion KRW | -4.53% |
2022 Q3 | 157.38 Billion KRW | 194.55% |
2022 Q1 | 51.02 Billion KRW | 397.52% |
2021 FY | 10.25 Billion KRW | -24.43% |
2021 Q3 | 11.51 Billion KRW | -8.84% |
2021 Q2 | 12.63 Billion KRW | -8.53% |
2021 Q1 | 13.81 Billion KRW | 1.76% |
2021 Q4 | 10.25 Billion KRW | -10.95% |
2020 FY | 13.57 Billion KRW | 131.67% |
2020 Q2 | 6.85 Billion KRW | -9.93% |
2020 Q4 | 13.57 Billion KRW | -12.42% |
2020 Q3 | 15.49 Billion KRW | 126.16% |
2020 Q1 | 7.6 Billion KRW | 29.86% |
2019 Q4 | 5.85 Billion KRW | 0.0% |
2019 FY | 5.85 Billion KRW | 0.0% |
2018 FY | - KRW | 0.0% |
2017 FY | - KRW | 0.0% |
2016 FY | - KRW | 0.0% |
2015 FY | - KRW | 0.0% |
2014 FY | - KRW | 0.0% |
2013 FY | - KRW | 0.0% |
2012 FY | - KRW | 0.0% |
2011 FY | - KRW | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
ORIENT BIO Inc. | 2.43 Billion KRW | -3777.76% |
Green Cross Holdings Corporation | 216.35 Billion KRW | 56.329% |
Green Cross Holdings Corporation | 84.89 Billion KRW | -11.301% |
Pharmicell Co., Ltd. | 390.21 Million KRW | -24113.108% |
Green Cross Corporation | 84.89 Billion KRW | -11.301% |
GeneOne Life Science, Inc. | 6.27 Billion KRW | -1406.254% |
Celltrion, Inc. | 99.13 Billion KRW | 4.69% |
Samsung Biologics Co.,Ltd. | 377.39 Billion KRW | 74.964% |
SK bioscience Co.,Ltd. | 12.43 Billion KRW | -659.757% |
Prestige BioPharma Limited | 40.87 Billion KRW | -131.174% |